Biotech Archives - Page 107 of 795

4 minute read

Reviva to Host KOL Event To Discuss Topline Data From Phase 3 RECOVER Trial Of Brilaroxazine In Schizophrenia

February 6, 9:13 AM

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system

RVPH

3 minute read

Seer Proteograph Enables Unprecedented Genetic Marker Mapping For Proteogenomics Studies To Advance Drug And Biomarker Discovery

By Benzinga Newsdesk

February 6, 9:10 AM

Study led by Weill Cornell Medicine demonstrates identification of protein altering variants for population-scale protein quantitative trait loci (pQTL) studies Proteograph Product Suite enables scalable deep,

SEER

3 minute read

UNITY Biotechnology, Inc. Announces New Publication In Nature Medicine Supports Therapeutic Potential Of Senolytics To Provide Long-lasting, Disease-Modifying Intervention In Vision Loss

By Benzinga Newsdesk

February 6, 9:04 AM

UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced new research published in the peer-reviewed journal Nature

UBX

2 minute read

Iridex Corporation Receives European Patent On MicroPulse Technology EP 3009093, Entitled “Laser System With Short Pulse Characteristics And Its Methods Of Use”

By Benzinga Newsdesk

February 6, 9:03 AM

Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today

IRIX

1 minute read

Aprea Therapeutics Announces Submission Of IND Application For APR-1051, A Next Generation WEE1 Kinase Inhibitor

By Benzinga Newsdesk

February 6, 9:03 AM

Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has submitted an

APRE

2 minute read

Twist Bioscience Launches cfDNA Library Preparation Kit For Liquid Biopsy Applications

By Benzinga Newsdesk

February 6, 9:02 AM

High accuracy and detection to identify tumor variants from degraded and low input samples as well as samples with limited DNA abundanceLibrary preparation kit adds to Twist's portfolio of tools to enable liquid biopsy

TWST

2 minute read

Lipocine Announces Confirmation Of Dosing Regimen For Pivotal Study Of LPCN 1154

By Benzinga Newsdesk

February 6, 9:02 AM

Positive clinical study results confirm 48-hour dosing regimen for the pivotal PK studyOn track for Q2-24 pivotal study topline results and planned Q4-24 NDA filing SALT LAKE CITY, Feb. 6, 2024 /PRNewswire/ --

LPCN

4 minute read

Vertex Announces Results From Pivotal Trials Of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment For Cystic Fibrosis

By Benzinga Newsdesk

February 5, 5:02 PM

– Treatment with the once-daily vanza triple CFTR modulator regimen met all primary and key secondary endpoints in two randomized controlled trials in people with CF ages 12 years and older –– Results were more

VRTX

2 minute read

New Hope For Patients With Chronic Autoimmune Conditions: Johnson & Johnson’s Investigational Drug Meets Primary Goal In Two Studies

By Vandana Singh

February 5, 2:10 PM

Johnson & Johnson's nipocalimab shows promise in Phase 3 VIVACITY for gMG & Phase 2 DAHLIAS for SjD. FDA-approved Vyvgart Hytrulo for gMG.

ARGX

1 minute read

MorphoSys Stock Soars After Report Says Novartis To Acquire Cancer-Drug Developer

By Erica Kollmann

February 5, 1:31 PM

Novartis is in advanced talks to acquire MorphoSys and appears to be beating out Incyte Corporation which has also made an offer to acquire MorphoSys. MorphoSys produces a lymphoma drug, Monjuvi, sold as part of a profit-sharing agreement with Incyte, which saw net product sales of $92 million in 2023. MorphoSys also is developing Pelabresib, an inhibitor of proteins involved in the development and progression of myelofibrosis.

INCY